Oslo, Norway, 14 May 2007
Clavis Pharma ASA has appointed Bo Nilsson as new Chief Medical Officer (CMO). Nilsson has extensive drug development experience from the international pharmaceutical industry.
Bo Nilsson (59), a Swedish national, is a qualified specialist within cancer and blood diseases. He has a wealth of experience in blue chip pharma development. For the last 20 years Nilsson has held senior medical positions in both small and large pharmaceutical companies. Most recently Nilsson held the position of Chief Medical Officer in Unibioscreen S.A. in Belgium
Mr. Nilsson is a licensed physician and holds a degree as M.D. from the University of Gothenburg. Nilsson is Board Certified in Sweden within the areas of Internal Medicine and Hematology.
"Further development of our drug candidates and technology are of key importance to the future progress of Clavis Pharma. We are therefore very satisfied to be joined by a colleague with Bo's extensive drug development background. His wealth of experience in developing products for large pharmaceutical companies as well as his knowledge of the US market will undoubtedly add tremendous value to our company", says Tom E. Pike, CEO of Clavis Pharma.
For further information, please contact:
Tom E. Pike
CEO
Tel: +47 915 19 652
tom.pike@clavispharma.com
www.clavispharma.com
About Clavis Pharma
Clavis Pharma ASA is a public oncology focused pharmaceutical company leveraging its proprietary Lipid Vector Technology (LVT)
platform to create New Chemical Entities (NCEs) by significantly improving approved drugs. The improvement is achieved by
chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated
suggests the resulting patentable NCEs offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties,
greater tissue penetration and, in many cases, additional modes of action.
Clavis Pharma intends to develop its drug candidates until significant value has been created and proof of principle in man has been shown. For further clinical development and commercialisation of the products, Clavis Pharma will enter strategic partnerships with established pharmaceutical or biotech companies. The company's product portfolio includes three new cancer drugs, of which the first ELACYTTM, is in clinical phase II, the second, CP-4126, is in clinical phase I, and the third is in the pre-clinical phase. Results indicate that ELACYTTM has a promising potential for several cancer indications within solid tumours and leukaemia.
Clavis Pharma ASA is listed on the Oslo Stock Exchange (ticker: CLAVIS). Additional information on Clavis Pharma can be found at: www.clavispharma.com